Indra Nooyi (Co-Chair)
Board co-chair of AdvanceCT; former CEO of PepsiCo
Indira NooyidirectedPepsiCo’s global strategy for more than a decade and was the chief architect of Performance with Purpose, the company’spledge to do what’s right for the business by being responsive to the needs of the world around us. She’s previously held leadership roles at ASEABrown Boveri, the Boston Consulting Group, and Johnson & Johnson. She serves on the boards of Amazon, Schlumerger Ltd, and the World Economic Forum, is a director of the International Cricket Council, and is a member of the American Academy of Arts and Sciences. In 2007 the Government of India awarded her the country’s thirdhighest civilian honor and she was named an “Outstanding American by Choice” by the US State Department.
Dr. Albert Ko (Co-Chair)
Professor of epidemiology and medicine and department chair at the Yale School of Public Health
Dr. Albert IcksangKo, an infectious disease physician, is a Professor and Chair of the Department of Epidemiology of Microbial Diseases at Yale School of Public Health and Collaborating Researcher at the Oswaldo Cruz Foundation, Brazilian Ministry of Health. His research centers on the health problems that have emerged as a consequence of rapid urbanization and social inequity. He is now coordinating research efforts to respond to the current COVID-19 outbreak at Yale and in the broader community.
Technology Company Chairman
As a technological innovator, Chuckwu is currently the executive chairman of a cloud-based software company, Aventri. As a child, Chukwu's family fled to the United States from Nigeria during their civil war.
Partner and managing director of Deerfield; co-founder and board member of The Institute for Life Changing Medicines
Alex Karnal joined the Firm in 2005 and is responsible for portfolio decisions and allocations across the Deerfield Funds.He is also a co-founder and board member of The Institute for Life Changing Medicines, dedicated to saving one million people suffering from life-threatening and devastating diseases around the world with no barriers to access. Mr. Karnal was featured in the 2020 edition of “The top20 under 40: Inside the next generation of biopharma leaders –Endpoints News."
Dr. Mehmood Khan
CEO and board member of Life Biosciences, Inc.
Dr. Khan has a distinguished medical career as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School and the Hennepin County Medical Center in Minneapolis. He’s also served as Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo where he played a pivotal role in the global R&D efforts to create breakthrough innovations in food, beverages and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio.
Dr. Harlan Krumholz
M.D., S.M., Yale University School of Medicine
Harlan Krumholz is a cardiologist and the Harold H.Hines, Jr. Professor of Medicine at Yale University where he leads the Center for Outcomes Research and Evaluation (CORE), which is dedicated to producing innovations to improve patient outcomes and promote better population health. He is a leading expert in the science of improving the quality and efficiency of care, reducing disparities, improving integrity in medical research, and avoiding wasteful practices. With several top honors and awards under his belt he was named one of thetop-cited scientists with a H-index (a measure of influence) of almost 200.
Charles Lee, Ph.D.
FACMG, Scientific Director and Professor, The Jackson Laboratory for Genomic Medicine
Dr. is best known for his discovery that copy--number variation—a statein which cells have an abnormal number of DNA sections. Giving the world an accurate diagnostic tool for conditions like autism, birth defects and cancer. Throughout his career, Dr. Lee has received numerous accolades and awards for his research into the human genome.
David I. Scheer
President of Scheer & Company; Former chairman of Achillion Pharmaceuticals
David Scheeris President of Scheer & Company, Inc., a firm founded in 1981, with activities in venture capital, corporate strategy, and transactional advisory services focused on the life sciences.Mr. Scheer has also led or played a significant role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. In 2013, he was the recipient of the Yale Science and Engineering Association Award for Distinguished Service to Industry, Commerce, and Education.